Fosun Pharmaceutical Shanghai Sells 1,300 Shares of Nature's Sunshine Products, Inc. (NASDAQ:NATR) Stock

Nature's Sunshine Products, Inc. (NASDAQ:NATR - Get Free Report) major shareholder Fosun Pharmaceutical Shanghai sold 1,300 shares of Nature's Sunshine Products stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $13.12, for a total value of $17,056.00. Following the sale, the insider now directly owns 66,467 shares in the company, valued at approximately $872,047.04. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Fosun Pharmaceutical Shanghai also recently made the following trade(s):

• On Thursday, October 10th, Fosun Pharmaceutical Shanghai sold 3,000 shares of Nature's Sunshine Products stock. The stock was sold at an average price of $13.39, for a total value of $40,170.00.
• On Tuesday, October 8th, Fosun Pharmaceutical Shanghai sold 1,800 shares of Nature's Sunshine Products stock. The stock was sold at an average price of $13.13, for a total value of $23,634.00.
• On Tuesday, October 1st, Fosun Pharmaceutical Shanghai sold 1,399 shares of Nature's Sunshine Products stock. The shares were sold at an average price of $13.54, for a total value of $18,942.46.

Nature's Sunshine Products Stock Down 0.8 %

Shares of NASDAQ:NATR traded down $0.10 during trading on Tuesday, hitting $12.92. 30,759 shares of the company traded hands, compared to its average volume of 54,114. The stock has a market capitalization of $241.99 million, a price-to-earnings ratio of 15.20 and a beta of 0.87. The business's fifty day moving average is $13.42 and its 200-day moving average is $15.53. Nature's Sunshine Products, Inc. has a one year low of $10.81 and a one year high of $21.72.

Nature's Sunshine Products (NASDAQ:NATR - Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.18). The company had revenue of $110.55 million for the quarter. Nature's Sunshine Products had a net margin of 3.50% and a return on equity of 9.79%.

Wall Street Analysts Forecast Growth

NATR has been the subject of several research analyst reports. StockNews.com raised Nature's Sunshine Products from a "buy" rating to a "strong-buy" rating in a report on Tuesday, September 10th. DA Davidson lowered their price objective on Nature's Sunshine Products from $23.00 to $21.00 and set a "buy" rating for the company in a report on Monday, August 12th. Canaccord Genuity Group initiated coverage on Nature's Sunshine Products in a report on Friday, September 13th. They issued a "buy" rating and a $18.00 price objective for the company. Finally, Canaccord Genuity Group initiated coverage on Nature's Sunshine Products in a report on Friday, September 13th. They issued a "buy" rating and a $18.00 price objective for the company.

Hedge Funds Weigh In On Nature's Sunshine Products

Several institutional investors have recently made changes to their positions in NATR. Jacobs Levy Equity Management Inc. boosted its position in shares of Nature's Sunshine Products by 1.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 58,507 shares of the company's stock worth $1,215,000 after buying an additional 927 shares during the period. Lazard Asset Management LLC boosted its position in shares of Nature's Sunshine Products by 16.5% during the first quarter. Lazard Asset Management LLC now owns 7,040 shares of the company's stock worth $146,000 after buying an additional 998 shares during the period. Gladius Capital Management LP boosted its position in shares of Nature's Sunshine Products by 23.9% during the second quarter. Gladius Capital Management LP now owns 6,862 shares of the company's stock worth $103,000 after buying an additional 1,325 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Nature's Sunshine Products by 12.7% during the first quarter. BNP Paribas Financial Markets now owns 15,207 shares of the company's stock worth $316,000 after buying an additional 1,715 shares during the period. Finally, Janney Montgomery Scott LLC boosted its position in shares of Nature's Sunshine Products by 8.9% during the first quarter. Janney Montgomery Scott LLC now owns 25,200 shares of the company's stock worth $523,000 after buying an additional 2,054 shares during the period. 79.40% of the stock is owned by institutional investors.

Nature's Sunshine Products Company Profile

Nature's Sunshine Products, Inc, a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision.